Qualitative and quantitative changes of human tenascin expression in transformed lung fibroblast and lung tumor tissues: comparison with fibronectin
- PMID: 1716516
Qualitative and quantitative changes of human tenascin expression in transformed lung fibroblast and lung tumor tissues: comparison with fibronectin
Abstract
Qualitative and quantitative alterations of human tenascin (TN) expression in virally transformed lung fibroblasts and in lung tumor tissues were investigated using S1 nuclease protection analysis in comparison with those of fibronectin (FN). Transformed fibroblasts and fetal lung tissues expressed more TN mRNA with an extra sequence encoding the sixth FN type III repeat than did normal cells and adult tissues. The splicing pattern of TN mRNA was also altered in many lung cancer tissues, showing increased or sometimes decreased expression of the TN mRNA with the extra sequence when compared with their surrounding normal tissues. These results provide additional evidence for the oncodevelopmental regulation of alternative RNA splicing in human lung tissues, first observed with FN mRNA (F. Oyama, et al., Cancer Res., 50: 1075-1078, 1990). Quantitative analysis of the levels of TN and FN mRNAs showed that the ratio of TN mRNA to FN mRNA was significantly increased in transformed fibroblasts and in some lung tumor tissues, when compared with their normal counterparts. Among different types of lung tumors, a significant increase of the TN/FN ratio was observed with most squamous cell carcinoma but with only a small fraction of adenocarcinoma. Since TN has been shown to inhibit cell adhesion to FN, the altered ratio of TN mRNA to FN mRNA may well affect the adhesive and migratory properties of tumor cells in lung cancer tissues.
Similar articles
-
Oncodevelopmental regulation of the alternative splicing of fibronectin pre-messenger RNA in human lung tissues.Cancer Res. 1990 Feb 15;50(4):1075-8. Cancer Res. 1990. PMID: 2297755
-
Extracellular matrix proteins in colorectal carcinomas. Expression of tenascin and fibronectin isoforms.Lab Invest. 1995 Aug;73(2):172-82. Lab Invest. 1995. PMID: 7543628
-
Tenascin-C, over expressed in lung cancer down regulates effector functions of tumor infiltrating lymphocytes.Lung Cancer. 2005 Jan;47(1):17-29. doi: 10.1016/j.lungcan.2004.05.016. Lung Cancer. 2005. PMID: 15603851
-
Expression of tenascin and of the ED-B containing oncofetal fibronectin isoform in human cancer.Cell Differ Dev. 1990 Dec 2;32(3):401-8. doi: 10.1016/0922-3371(90)90056-3. Cell Differ Dev. 1990. PMID: 1711919 Review.
-
Tenascin-C in peripheral nerve morphogenesis.Perspect Dev Neurobiol. 1994;2(1):67-74. Perspect Dev Neurobiol. 1994. PMID: 7530145 Review.
Cited by
-
Tenascin-C and human tendon degeneration.Am J Pathol. 1996 Sep;149(3):933-43. Am J Pathol. 1996. PMID: 8780397 Free PMC article.
-
Cell surface annexin II is a high affinity receptor for the alternatively spliced segment of tenascin-C.J Cell Biol. 1994 Jul;126(2):539-48. doi: 10.1083/jcb.126.2.539. J Cell Biol. 1994. PMID: 7518469 Free PMC article.
-
A novel tenascin type III repeat is part of a complex of tenascin mRNA alternative splices.Nucleic Acids Res. 1993 Jan 11;21(1):163-8. doi: 10.1093/nar/21.1.163. Nucleic Acids Res. 1993. PMID: 7680113 Free PMC article.
-
Tenascin-C: Form versus function.Cell Adh Migr. 2015;9(1-2):48-82. doi: 10.4161/19336918.2014.987587. Cell Adh Migr. 2015. PMID: 25482829 Free PMC article. Review.
-
Tenascin-C serum levels and its prognostic power in non-small cell lung cancer.Oncotarget. 2016 Apr 12;7(15):20945-52. doi: 10.18632/oncotarget.7976. Oncotarget. 2016. PMID: 26967391 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Miscellaneous